Display Settings:

Format

Send to:

Choose Destination
Crit Rev Oncol Hematol. 2011 Nov;80(2):257-63. doi: 10.1016/j.critrevonc.2010.10.007. Epub 2010 Nov 4.

Angiosarcoma: state of the art and perspectives.

Author information

  • 1EORTC Headquarters, Belgium. n-penel@o-lambret.fr

Abstract

We propose a literature review of available data on angiosarcoma (AS). AS account for 1% of adult soft tissue sarcoma. Two risk factors are well-establish chronic lymhoedema, previous radiotherapy. Clinical presentations of AS are heterogeneous. Large resection followed, if possible, by adjuvant radiotherapy is the cornerstone of curative intent treatment of localized forms. There are no convincing data supporting the administration of adjuvant chemotherapy. For metastatic or locally advanced AS, doxorubicin and weekly paclitaxel seem to provide the longer progression-free survival. Three phase II or parts of phase II trials have been published in the last 2 years, investigating weekly paclitaxel, sorafenib and imatinib, demonstrating that clinical trials are feasible for such rare diseases. Biological evidences for the key role of angiogentic factors have been accumulated during the last years and support the further investigation of anti-angiogenetic agents alone and almost combination with chemotherapy in such disease.

Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

PMID:
21055965
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk